Cynomolgus / Rhesus PD-L1 / B7-H1 / CD274 Protein (His Tag)

Programmed death-1 ligand-1 (PD-L1, CD274, B7-H1) has been identified as the ligand for the immunoinhibitory receptor programmed death-1(PD1/PDCD1) and has been demonstrated to play a role in the regulation of immune responses and peripheral tolerance. PD-L1/B7-H1 is a member of the growing B7 family of immune molecules and this protein contains one V-like and one C-like Ig domain within the extracellular domain, and together with PD-L2, are two ligands for PD1 which belongs to the CD28/CTLA4 family expressed on activated lymphoid cells. By binding to PD1 on activated T-cells and B-cells, PD-L1 may inhibit ongoing T-cell responses by inducing apoptosis and arresting cell-cycle progression. Accordingly, it leads to growth of immunogenic tumor growth by increasing apoptosis of antigen specific T cells and may contribute to immune evasion by cancers. PD-L1 thus is regarded as promising therapeutic target for human autoimmune disease and malignant cancers.

• Cancer Immunotherapy
• Co-inhibitory Immune Checkpoint Targets
• Immune Checkpoint
• Immune Checkpoint Blockade: Blocking Antibodi
• Immune Checkpoint Blockade: PD-L1 / B7-H1 / C
• Immune Checkpoint Detection: Antibodies
• Immune Checkpoint Detection: ELISA Antibodies
• Immune Checkpoint Detection: FCM Antibodies
• Immune Checkpoint Detection: ICC Antibodies
• Immune Checkpoint Detection: IHC Antibodies
• Immune Checkpoint Detection: WB Antibodies
• Immune Checkpoint Proteins
• Immune Checkpoint Targets
• Immunotherapy
• PD-L1 / B7-H1 / CD274 Immune Checkpoint Prote
• Targeted Therapy

CD274 molecule

• Immunology>>Adaptive Immunity>>Costimulation & Costimulatory Molecule>>B7/CD28 Family
• Immune Checkpoint>>Co-inhibitory Immune Checkpoint
• Immunology>>Innate Immunity>>Monocytes/Macrophages>>Co-stimulatory Molecules
• Developmental Biology>>Embryogenesis>>Germ Layer Formation>>Ectoderm Marker
• Immunology>>Innate Immunity>>Monocytes/Macrophages>>Macrophage Markers
• Immunology>>Inflammation / Inflammatory Mediator>>Cells Involved in Inflammation>>Myeloid-derived Suppressor Cells (MDSC)
• Immunology>>Cluster of Differentiation (CD)>>Natural Killer (NK) Cell CD Antigen
• Immunology>>Cluster of Differentiation (CD)>>Dendritic Cell CD Antigen>>Other Dendritic Cell CD Antigen
• Immunology>>Cluster of Differentiation (CD)>>Monocyte/Macrophage CD Antigen>>Other Monocytes/Macrophages CD Antigen

• Iwai Y, et al. (2002) Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A. 99(19): 12293-7.
• Ghebeh H, et al. (2006) The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia. 8(3): 190-8.
• Salih HR, et al. (2006) The role of leukemia-derived B7-H1 (PD-L1) in tumor-T-cell interactions in humans. Exp Hematol. 34(7): 888-94.
• Wilcox RA, et al. (2009) B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders. Blood. 114(10): 2149-58.
• Ruggiero A, et al. (2009) Crystal structure of PD-L1, a ribosome inactivating protein from Phytolacca dioica L. leaves with the property to induce DNA cleavage. Biopolymers. 91(12): 1135-42.